Skip to main content

Table 2 Senescence-associated secretory phenotype in pEOCs undergoing spontaneous and drug-induced senescence in vitro and in vivo

From: Pro-cancerogenic effects of spontaneous and drug-induced senescence of ovarian cancer cells in vitro and in vivo: a comparative analysis

 

No drugs (spontaneous)

CPT + PCT in vitro

CPT + PCT in vivo

Process

Protein

young

senescent

senescent

young

senescent

Angiogenesis

ANG1 (pg/105 cells)

654 ± 316

5787 ± 1171a

2353 ± 356a*

1510 ± 343a

3186 ± 631b*

bFGF (pg/105 cells)

6 ± 1

44 ± 5a

49 ± 5a

5 ± 1

30 ± 8b

CXCL8/IL-8 (pg/105 cells)

129 ± 48

613 ± 54a

748 ± 142a

138 ± 61

414 ± 134b*

FGF5 (fg/105 cells)

839 ± 98

7034 ± 181a

2873 ± 89a*

1554 ± 163a

4982 ± 212b*

VEGF (pg/105 cells)

89 ± 18

228 ± 42a

132 ± 22a*

91 ± 35

283 ± 48b

ECM remodeling and invasion

ADAM12 (pg/105 cells)

254 ± 63

2330 ± 562a

646 ± 81a*

802 ± 348a

1496 ± 255b*

PDGF-D (fg/105 cells)

625 ± 134

6695 ± 1354a

2411 ± 771a*

762 ± 235

4485 ± 622b*

tPA (pg/105 cells)

41 ± 9

343 ± 53a

282 ± 19 a*

118 ± 26a

169 ± 13 b*

TGF-β1 (pg/105 cells)

19 ± 6

107 ± 33a

29 ± 3*

12 ± 4

31 ± 9 b*

TIMP-1 (pg/105 cells)

473 ± 127

3802 ± 592a

1613 ± 304a*

858 ± 346a

2702 ± 369b*

TSP-1 (ng/105 cells)

11 ± 2

93 ± 11a

39 ± 5a*

21 ± 4a

69 ± 8b*

uPA (pg/105 cells)

33 ± 9

104 ± 25a

78 ± 20

24 ± 4

104 ± 11b

Inflammation

CCL2/MCP-1 (pg/105 cells)

130 ± 37

1131 ± 230a

470 ± 57a*

273 ± 28a

776 ± 90b*

ICAM-1 (pg/105 cells)

256 ± 48

830 ± 143a

607 ± 80a*

241 ± 38

694 ± 135

IL-6 (pg/105 cells)

25 ± 6

482 ± 154a

119 ± 7a*

65 ± 15a

449 ± 33b

VCAM-1 (pg/105 cells)

64 ± 16

285 ± 76a

144 ± 30a*

107 ± 25a

275 ± 63

Proliferation and migration

CCL11 (pg/105 cells)

45 ± 12

364 ± 69a

148 ± 26a*

80 ± 33a

254 ± 32b

CXCL1/GRO-1 (pg/105 cells)

75 ± 11

497 ± 100a

572 ± 143a

204 ± 111a

532 ± 88b

CXCL12/SDF-1 (pg/105 cells)

2 ± 1

14 ± 5a

5 ± 1a*

3 ± 1

9 ± 2b

CXCL5 (pg/105 cells)

16 ± 4

37 ± 11a

149 ± 24a*

31 ± 7a

43 ± 15

EGF (fg/105 cells)

744 ± 23

4268 ± 199a

2831 ± 508a*

3175 ± 757a

5002 ± 449b

HGF (pg/105 cells)

30 ± 6

239 ± 22a

54 ± 14*

15 ± 3a

59 ± 6b*

IGF-1 (pg/105 cells)

15 ± 5

124 ± 28a

37 ± 3a*

12 ± 6

616 ± 179b*

NRP-1 (pg/105 cells)

62 ± 18

494 ± 86a

206 ± 34a*

114 ± 47a

358 ± 50b

  1. Note that “young” cells in the “no drugs” group are common for “no drugs” senescent cells and “CPT + PCT in vitro senescent” cells (they originate from the same donor). Experiments were performed using pEOC cultures obtained from 8 different patients (in the “no drugs” and “CPT + PCT in vivo” groups, respectively). The results are expressed as mean ± SEM. aP < 0.05 vs. young no drugs cells; bP < 0.05 vs. young CPT + PCT in vivo cell; *—P < 0.05 vs. senescent no drugs cells